
Cellectis and AstraZeneca in US$2.2bn deal
Under the co-development agreement, that includes a US$80m equity investment and an option for a further equity investment of US$140m by AstraZeneca...

Breakthrough in COPD treatment
Sanofi's duplimab (Dupixent®) showcased notable efficacy in reducing exacerbations and enhancing lung function in its second positive Phase III...

BioLamina AB bags €19m funding for expansion
The tenth investement from Lauxera Capital Partners through its Lauxera Growth I fund will be usesd by the Swedish company to expand the development...

Spain set to unveil the potential of the biologisation of medicine and food production
At BioSpain 2023, several panels discussed the Spanish EU Presidency's goal of setting the course for the internationally competitive use of...

Unveiling prostate cancer's Achilles' heel
An international research team, including experts from IRB Barcelona, Max Planck Institute for Molecular Genetics, and BC Cancer, discovered a...

Germany boosts protein transition with €38m
Germany is set to follow countries such as the Denmark, the UK and the Netherlands, which this year provided massive funding to become world...

SeaBeLife secures €1.2m in funding
SeaBeLife SAS has secured €1.2m in funding, aiming to develop unique drug candidates that block cell necrosis and target two regulated cell death...